Document is current

Documents that mention this clinical trial

Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
https://doi.org/10.1136/jitc-2019-000356

Strategies for improving the management of immune-related adverse events
https://doi.org/10.1136/jitc-2020-001754

Incidence of immune checkpoint inhibitor–mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score–matched retrospective study
https://doi.org/10.1136/jitc-2021-002567

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
https://doi.org/10.1136/jitc-2021-003956

Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study
https://doi.org/10.1136/jitc-2020-000538

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
https://doi.org/10.1136/jitc-2022-006658